Vanessa Monsef
Nurse Practitioner · Vancouver, WANPI 1548937758
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $882 and has fallen 89.1% since, to $96 in 2023. Among nurse practitioner clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$200
- Novo Nordisk$112
- Amgen$98
- AbbVie$90
- Johnson & Johnson$82
- GRT US Holding, Inc.$81
- plus $459 from 10 others
What the payments were for
- Food & beverage$1,117100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 11 | $200 |
| Novo Nordisk | 5 | $112 |
| Amgen | 4 | $98 |
| AbbVie | 6 | $90 |
| Johnson & Johnson | 4 | $82 |
| GRT US Holding, Inc. | 1 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $73 |
| Pfizer | 3 | $71 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $71 |
| Lilly USA, LLC | 4 | $64 |
| Boehringer Ingelheim | 2 | $54 |
| AstraZeneca | 3 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $31 |
| Exact Sciences | 1 | $22 |
| GSK | 1 | $16 |
| Bausch Health US, LLC | 1 | $16 |
How this compares
$1,121 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 13 | $26,979 |
| JardianceEmpagliflozin | 20 | $26,672 |
| MounjaroTirzepatide | 17 | $17,440 |
| EliquisApixaban | 12 | $14,371 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $2,120 |
| Memantine Hcl | 18 | $1,827 |
| Atorvastatin Calcium | 150 | $1,649 |
| Levothyroxine Sodium | 123 | $1,435 |
| Gabapentin | 67 | $1,427 |
| Duloxetine Hcl | 59 | $1,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,157 |
| ValacyclovirValacyclovir Hcl | 19 | $1,076 |
| Metoprolol Succinate | 47 | $1,044 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $967 |
| Tamsulosin Hcl | 34 | $917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $112 | $26,97913 claims |
| Boehringer IngelheimJardiance | $54 | $26,67220 claims |
| Lilly USA, LLCMounjaro | $64 | $17,44017 claims |
| PfizerEliquis | $71 | $14,37112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Vancouver
- Bryant MotykowskiVancouver$5K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
- Jessica ArmitageSumner$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.